Catalent Belgium SA – FDA 483, Aug 19, 2022
An FDA inspection of Catalent Belgium SA, a finished drug product manufacturer in Brussels, revealed nine significant deficiencies. These observations highlight a broad range of issues impacting the firm's compliance with good manufacturing practices, including problems with aseptic processing, deviation investigations, process controls, equipment qualification, data integrity, design history files, purchasing controls, and internal quality audits. The findings indicate a need for comprehensive corrective actions across multiple quality system areas.
ID · 39127879-6006-4bf9-9097-c58baca0283e
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.